

Kurzfassung der S3-Leitlinie „Helicobacter pylori und gastroduodenale Ulkuskrankheit“ der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten

W. Fischbach für die Leitliniengruppe
aus BDI aktuell 11/2009

Literatur

- 1 Brenner H, Weyermann M, Rothenbacher D. Clustering of *Helicobacter pylori* infection in couples: differences between high- and low-prevalence population groups. *Ann Epidemiol* 2006; 16 (7): 516–520
- 2 Cutler AF, Havstad S, Ma CK, Blaser MJ, Perez-Perez GI, Schubert TT. Accuracy of invasive and noninvasive tests to diagnose *Helicobacter pylori* infection. *Gastroenterology* 1995; 109 (1): 136–141
- 3 Fischbach W, Malfertheiner P, Hoffmann JC et al. S3-Leitlinie „*Helicobacter pylori* und gastroduodenale Ulkuskrankheit“ der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). In Zusammenarbeit mit der Deutschen Gesellschaft für Hygiene und Mikrobiologie, Gesellschaft für Pädiatrische Gastroenterologie und Ernährung e. V. und der Deutschen Gesellschaft für Rheumatologie – AWMF-Register-Nr. 021/001. *Z Gastroenterol* 2009; 47: 68–102
- 4 Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive *Helicobacter pylori* eradication therapy: experience from a large prospective series. *Gut* 2004; 53: 34–37
- 5 Fischbach W, Goebeler ME, Ruskone-Fourmestreaux A et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of *Helicobacter pylori* can be managed safely by a watch and wait strategy: experience from a large international series. *Gut* 2007; 56: 1685–1687
- 6 Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in *Helicobacter pylori* positive patients. *Cochrane Database Syst Rev* 2006(2CD003840)
- 7 Forman D, Newell DG, Fullerton F et al. Association between infection with *Helicobacter pylori* and risk of gastric cancer: evidence from a prospective investigation. *Brit med J* 1991; 302: 1302–1305
- 8 Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after *Helicobacter pylori* treatment failure. *Aliment Pharmacol Ther* 2006; 23: 35–44
- 9 Grimm W, Fischbach W. *Helicobacter pylori*-Infektion bei Kindern und Jugendlichen. Eine epidemiologische Untersuchung zu Prävalenz, sozioökonomischen Faktoren und Beschwerdebild. *Dtsch Med Wochenschr* 2003; 128: 1878–1883
- 10 Hooper L, Brown TJ, Elliott R et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. *Brit Med J* 2004; 329: 948
- 11 Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. *Brit Med J* 2006; 332: 1302–1308
- 12 Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with *Helicobacter pylori*-associated gastric or duodenal ulcer. *Aliment Pharmacol Ther* 2001; 15: 1949–1958
- 13 Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El Omar E, Graham D et al. Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. *Gut* 2007; 56 (6): 772–781
- 14 Malfertheiner P, Layer P, Fischbach W, Mössner J. *Helicobacter pylori* eradication is beneficial in the treatment of functional dyspepsia. *Alimentary Pharmacol Ther* 2003; 18 (6): 615–625
- 15 Miehle S, Schneider-Brachert W, Kirsch C et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent *Helicobacter pylori* resistant to both metronidazole and clarithromycin. *Helicobacter* 2008; 13: 69–74

- 16** Parsonnet J. The incidence of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 1995; 9 Suppl 2: 45–51
- 17** Parsonnet J, Hansen S, Rodriguez L et al. *Helicobacter pylori* infection and gastric lymphoma. *N Engl J Med* 1994; 330 (18): 1267–1271
- 18** Thijs JC, van Zwet AA, Thijs WJ, Oey HB, Karrenbeld A, Stellaard F et al. Diagnostic tests for *Helicobacter pylori*: a prospective evaluation of their accuracy, without selecting a single test as the gold standard. *Am J Gastroenterol* 1996; 91: 2125–2129
- 19** Warren JR, Marshall BJ. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984; I: 1311–1315
- 20** Zullo A, De Francesco V et al. The sequential therapy regimen for *Helicobacter pylori* eradication: a pooled-data analysis. *Gut* 2007; 56: 1353–7